Scancell (LON:SCLP) Stock Price Up 29.8% – Should You Buy?

Scancell Holdings plc (LON:SCLP)’s share price was up 29.8% during mid-day trading on Monday . The stock traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.14). Approximately 10,537,342 shares traded hands during mid-day trading, an increase of 1,073% from the average daily volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Price Performance

The firm’s fifty day simple moving average is GBX 8.43 and its 200-day simple moving average is GBX 10.88. The firm has a market capitalization of £113.93 million, a PE ratio of -16.86 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79.

Scancell (LON:SCLP) last released its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. On average, research analysts forecast that Scancell Holdings plc will post -2.5361112 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.